Johnson & Johnson Revenue 2006-2018 | JNJ

Johnson & Johnson annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Johnson & Johnson revenue for the quarter ending September 30, 2018 was $20.348B, a 3.55% increase year-over-year.
  • Johnson & Johnson revenue for the twelve months ending September 30, 2018 was $81.382B, a 9.44% increase year-over-year.
  • Johnson & Johnson annual revenue for 2017 was $76.45B, a 6.34% increase from 2016.
  • Johnson & Johnson annual revenue for 2016 was $71.89B, a 2.59% increase from 2015.
  • Johnson & Johnson annual revenue for 2015 was $70.074B, a 5.73% decline from 2014.
Johnson & Johnson Annual Revenue
(Millions of US $)
2017 $76,450
2016 $71,890
2015 $70,074
2014 $74,331
2013 $71,312
2012 $67,224
2011 $65,030
2010 $61,587
2009 $61,897
2008 $63,747
2007 $61,095
2006 $53,324
2005 $50,514
Johnson & Johnson Quarterly Revenue
(Millions of US $)
Q3 2018 $20,348
Q2 2018 $20,830
Q1 2018 $20,009
Q4 2017 $20,195
Q3 2017 $19,650
Q2 2017 $18,839
Q1 2017 $17,766
Q4 2016 $18,106
Q3 2016 $17,820
Q2 2016 $18,482
Q1 2016 $17,482
Q4 2015 $17,811
Q3 2015 $17,102
Q2 2015 $17,787
Q1 2015 $17,374
Q4 2014 $18,254
Q3 2014 $18,467
Q2 2014 $19,495
Q1 2014 $18,115
Q4 2013 $18,355
Q3 2013 $17,575
Q2 2013 $17,877
Q1 2013 $17,505
Q4 2012 $17,558
Q3 2012 $17,052
Q2 2012 $16,475
Q1 2012 $16,139
Q4 2011 $16,255
Q3 2011 $16,005
Q2 2011 $16,597
Q1 2011 $16,173
Q4 2010 $15,644
Q3 2010 $14,982
Q2 2010 $15,330
Q1 2010 $15,631
Q4 2009 $16,551
Q3 2009 $15,081
Q2 2009 $15,239
Q1 2009 $15,026
Q4 2008 $15,182
Q3 2008 $15,921
Q2 2008 $16,450
Q1 2008 $16,194
Q4 2007 $15,957
Q3 2007 $14,970
Q2 2007 $15,131
Q1 2007 $15,037
Q4 2006 $13,682
Q3 2006 $13,287
Q2 2006 $13,363
Q1 2006 $12,992
Q4 2005 $12,610
Q3 2005 $12,310
Q2 2005 $12,762
Q1 2005 $12,832
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $372.065B $76.450B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $264.129B 15.46
Novartis AG (NVS) Switzerland $201.850B 17.25
Merck (MRK) United States $195.663B 17.28
AbbVie (ABBV) United States $127.608B 12.47
Eli Lilly (LLY) United States $120.319B 22.27
Sanofi (SNY) France $111.710B 14.14
Novo Nordisk (NVO) Denmark $105.365B 16.84
GlaxoSmithKline (GSK) United Kingdom $100.437B 13.41
AstraZeneca (AZN) United Kingdom $100.024B 11.00
Bristol-Myers Squibb (BMY) United States $83.165B 15.05